C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

References

• Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57; PMID:16151408; http://dx.doi.org/10.1038/nbt1137
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Chouaib S, Meslin F, Thiery J, Mami-Chouaib F. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer. Clin Immunol 2009; 130:34-40; PMID:19013109; http://dx.doi.org/10.1016/j.clim.2008.08.020
   PubMed Web of Science ®Google Scholar
• Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22:3-13; PMID:22245472; http://dx.doi.org/10.1016/j.semcancer.2011.12.009
   PubMed Web of Science ®Google Scholar
• de Bruyn M, Wei Y, Wiersma VR, Samplonius DF, Klip HG, van der Zee AG, Yang B, Helfrich W, Bremer E. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells. Clin Cancer Res 2011; 17:5626-37; PMID:21753155; http://dx.doi.org/10.1158/1078-0432.CCR-11-0303
   PubMed Web of Science ®Google Scholar
• Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61; PMID:11801676; http://dx.doi.org/10.4049/jimmunol.168.3.1356
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7:94-100; PMID:11135622; http://dx.doi.org/10.1038/83416
   PubMed Web of Science ®Google Scholar
• Fox NL, Humphreys R, Luster TA, Klein J, Gallant G. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin Biol Ther 2010; 10:1-18; PMID:19857186; http://dx.doi.org/10.1517/14712590903319656
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A 2014; 111:930-5; PMID:24395803; http://dx.doi.org/10.1073/pnas.1316312111
   PubMed Web of Science ®Google Scholar
• Wiersma VR, He Y, Samplonius DF, van Ginkel RJ, Gerssen J, Eggleton P, Zhou J, Bremer E, Helfrich W. A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. Br J Haematol 2014; 164:304-7; PMID:24164421; http://dx.doi.org/10.1111/bjh.12617
   PubMed Web of Science ®Google Scholar
• Marshall A, Willment J, Lin H, Williams DL, Gordon S, Brown GD. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem 2004; 279:14792-802; PMID:14739280; http://dx.doi.org/10.1074/jbc.M313127200
   PubMed Web of Science ®Google Scholar
• Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004; 109:281-90; PMID:14750182; http://dx.doi.org/10.1002/ijc.11702
   PubMed Web of Science ®Google Scholar
• Jaganjac M, Poljak-Blazi M, Kirac I, Borovic S, Joerg Schaur R, Zarkovic N. Granulocytes as effective anticancer agent in experimental solid tumor models. Immunobiology 2010; 215:1015-20; PMID:20122752; http://dx.doi.org/10.1016/j.imbio.2010.01.002
   PubMed Web of Science ®Google Scholar
• Souto JC, Vila L, Bru A. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 2011; 31:311-63; PMID:19967776; http://dx.doi.org/10.1002/med.20185
   PubMed Web of Science ®Google Scholar
• Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, Le TT, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006; 177:8123-32; PMID:17114487; http://dx.doi.org/10.4049/jimmunol.177.11.8123
   PubMed Web of Science ®Google Scholar
• Brincks EL, Risk MC, Griffith TS. PMN and anti-tumor immunity-the case of bladder cancer immunotherapy. Semin Cancer Biol 2013; 23:183-9; PMID:23410637; http://dx.doi.org/10.1016/j.semcancer.2013.02.002
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Beyer T, Neuhuber W, Repp R, Kalden JR, Valerius T, Herrmann M. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 2003; 171:5124-9; PMID:14607911; http://dx.doi.org/10.4049/jimmunol.171.10.5124
   PubMed Web of Science ®Google Scholar
• Horner H, Frank C, Dechant C, Repp R, Glennie M, Herrmann M, Stockmeyer B. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J Immunol 2007; 179:337-45; PMID:17579054; http://dx.doi.org/10.4049/jimmunol.179.1.337
   PubMed Web of Science ®Google Scholar
• Bremer E, Samplonius DF, van GL, Dijkstra MH, Kroesen BJ, de Leij LF, Helfrich W. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005; 280:10025-33; PMID:15644326; http://dx.doi.org/10.1074/jbc.M413673200
   PubMed Web of Science ®Google Scholar
• Bremer E, van Dam G, de Bruyn M, van Riezen M, Dijkstra M, Kamps G, Helfrich W, Haisma H. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008; 16:1919-26; PMID:18813279; http://dx.doi.org/10.1038/mt.2008.203
   PubMed Web of Science ®Google Scholar
• Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991; 78:885-9; PMID:1714327
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, Repasky EA, Czuczman MS. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46:1775-84; PMID:16263581; http://dx.doi.org/10.1080/17402520500182329
   PubMed Web of Science ®Google Scholar
• Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012; 30:426-32; PMID:22203761; http://dx.doi.org/10.1200/JCO.2011.37.6236
   PubMed Web of Science ®Google Scholar
• Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Phase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumors. Gynecol Oncol 2010; 116:168-72; PMID:19922985; http://dx.doi.org/10.1016/j.ygyno.2009.10.075
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839-46; PMID:20458040; http://dx.doi.org/10.1200/JCO.2009.25.1991
   PubMed Web of Science ®Google Scholar
• Helfrich W, Haisma HJ, Magdolen V, Luther T, Bom VJ, Westra J, van der Hoeven R, Kroesen BJ, Molema G, de Leij L. A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions. J Immunol Methods 2000; 237:131-45; PMID:10725458; http://dx.doi.org/10.1016/S0022-1759(99)00220-3
   PubMed Web of Science ®Google Scholar
• de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 2010; 9:301; PMID:21092273; http://dx.doi.org/10.1186/1476-4598-9-301
   PubMed Web of Science ®Google Scholar